Artificial intelligence is shifting cancer treatment from finding natural drug targets to actively rewriting the genetic instructions that make tumors grow. Instead of hunting for proteins on cancer cells that drugs can hit, researchers are now using AI to decode the regulatory patterns that distinguish cancer cells from healthy ones, then designing genetic payloads that reprogram tumors to self-destruct. This represents a fundamental shift in how oncology approaches the disease .

The core challenge in cancer treatment has always been discrimination. At the molecular level, cancer cells and normal cells are nearly identical. What makes a cell cancerous is dysregulation, a set of genetic switches flipped in the wrong direction that causes uncontrolled growth. For decades, finding these switches required manually hunting through patient samples, looking for patterns so subtle they were almost invisible .

What Makes AI's Approach Different From Traditional Cancer Drugs?

Traditional oncology identifies naturally occurring targets on tumor cells, proteins, enzymes, or receptors, then builds drugs to hit them. This approach is slow, expensive, and profoundly limited because those same targets often exist in healthy cells. Any drug that activates the immune system against cancer also activates elsewhere, causing dangerous immune responses. The only current solution is reducing the dose, which also reduces effectiveness and increases the risk of cancer returning with drug-resistant mutations .

AI changes this equation entirely. Systems trained on genomic databases spanning tens of thousands of sequenced cancer samples can now identify the master regulatory patterns active specifically in cancer cells and not in surrounding healthy tissue. These are fine-grained genomic signatures that encode the difference between malignant and normal at the level of how genes are switched on and off .

"AI-driven cancer bioengineering decodes the rules of cancer's genetic circuits well enough to write programs that run inside tumor cells with a precision that natural biomarkers never permitted. We are not just reading the code. We are rewriting it," stated Cyriac Roeding, CEO of Earli, an early cancer treatment company.

Cyriac Roeding, CEO of Earli

Once those genetic signatures are identified, they unlock approaches that simply were not possible before. AI is helping researchers design personalized cancer vaccines that train the immune system against the unique mutations a patient's tumor produces. Moderna and Merck are already in late-stage trials using this approach, building on the same messenger RNA (mRNA) infrastructure that powered COVID-19 vaccines. AI is also helping engineers build smarter CAR T cells, which are immune cells engineered to recognize and attack cancer, that use tumor-specific signals to stay active inside the immunosuppressive environment of a cancer rather than exhausting themselves before the job is done .

How Are Researchers Delivering These Genetic Treatments to Tumors?

The delivery mechanism requires its own breakthrough. To reach a cancer cell, a synthetic genetic payload must travel through the body without being destroyed by the immune system. Lipid nanoparticles, the same technology behind COVID-19 vaccines, are emerging as the vehicle. The pandemic programs proved what researchers had long suspected: lipid nanoparticles could safely and at scale deliver mRNA payloads into human cells. Bioengineers are now adapting that infrastructure for cancer and for therapeutic, transient, and safe DNA payloads, engineering nanoparticle surfaces to evade immune detection and extend the window for reaching their target .

Meanwhile, complementary advances in sequencing technology are enabling researchers to profile tumors with unprecedented detail. A new collaboration between PacBio and Covaris announced in April 2026 enables highly accurate long-read sequencing from archived tumor samples stored in formalin-fixed, paraffin-embedded (FFPE) tissue, a format that has historically been incompatible with advanced sequencing .

In studies across brain, kidney, and uterine tumor samples, this combined workflow produced more than 100 million high-fidelity reads per sample, with mean read lengths of 750 to 1,500 base pairs. The data enabled detection of over 11,000 structural variants and more than 5 million small variants per sample, with approximately 60 percent phased into haplotypes. By comparison, short-read sequencing of FFPE tissue typically detects 3,000 to 7,000 structural variants per sample, less than half the yield achieved with long-read technology .

Steps to Unlock Archived Tumor Samples for AI-Driven Discovery

• Extract longer DNA fragments: Use acoustic-based extraction methods like Covaris' truXTRAC technology to recover DNA fragments up to 5,000 base pairs from FFPE tissues, overcoming historical fragmentation limitations.
• Concatenate fragments for sequencing: Apply library preparation methods like PacBio's Kinnex that concatenate recovered fragments into longer molecules suitable for high-fidelity sequencing and variant phasing.
• Generate comprehensive genomic profiles: Sequence samples to detect structural variants, small variants, and phase mutations into haplotypes, enabling AI models to identify cancer-specific regulatory patterns from archived clinical samples.

This ability to unlock vast archives of banked samples is significant. Researchers can now revisit these samples to uncover structural variation, phase mutations, and resolve complex genomic regions that have remained out of reach with short-read sequencing, ultimately accelerating progress in oncology .

Another emerging tool is ultrasensitive whole-genome sequencing for detecting minimal residual disease (MRD), the small number of cancer cells that may remain after treatment. Tempus AI and Predicta Biosciences announced a collaboration in April 2026 to expand access to GenoPredicta, an ultrasensitive assay that integrates flow cytometry with whole-genome sequencing to detect genetic alterations from as few as 50 tumor cells, corresponding to a sensitivity as low as one in a million cells .

"By consolidating flow cytometry, cytogenetics, and whole-genome sequencing into one ultrasensitive workflow, we can identify high-risk biomarkers and track clonal evolution from as few as 50 tumor cells. Crucially, because the assay delivers 100 percent concordance between peripheral blood and bone marrow, it can provide these deep insights while sparing patients from biopsies," explained Kate Sasser, Chief Scientific Officer at Tempus.

Kate Sasser, PhD, Chief Scientific Officer at Tempus

The assay has been clinically validated in multiple myeloma and other plasma cell dyscrasias and is available for research use across other hematologic malignancies. This sensitivity expands testing eligibility to cases with low tumor burden, enabling earlier detection and smarter treatment decisions .

Why This Matters for Cancer Survival Rates

In lung cancer, the deadliest form accounting for 1.8 million deaths globally every year, progress has been made and the five-year survival rate has nearly doubled over the past two decades. However, that still means approximately 70 percent of diagnosed patients will die within five years . AI-driven approaches to genetic reprogramming and early detection could shift these statistics significantly.

The analogy researchers are beginning to use is that this AI approach to cancer biology is what AlphaFold became to protein science. AlphaFold did not discover proteins; it decoded the rules governing how they fold, making it possible to reason about protein structure systematically for the first time. Similarly, AI-driven cancer bioengineering decodes the rules of cancer's genetic circuits well enough to write programs that run inside tumor cells with precision that natural biomarkers never permitted .

However, realizing this potential requires sustained investment. China has made biotechnology a national strategic priority, channeling government funds directly into biotech startups, cutting regulatory review timelines, and mounting a credible threat to American dominance in the sector. In the first half of 2025 alone, the pharmaceutical industry committed 48.5 billion dollars to Chinese biotech deals, more than all of 2024 combined. Meanwhile, U.S. venture capital continues to flow overwhelmingly toward artificial intelligence in the narrow software sense. AI startups attracted over 200 billion dollars in funding last year, representing 50 percent of all venture capital funding, while biopharma drew roughly 26 billion dollars .

For the U.S. to lead on the future of cancer treatment, experts argue that Congress should establish a dedicated national biotech investment fund that puts capital directly into early-stage platform companies and keeps intellectual property on American soil. Large institutional investors and venture capital firms must also recognize that a technology capable of programming cells to fight cancer deserves at least the same urgency as the next large language model. Finally, the FDA's expedited review pathways need to be extended explicitly to platform-based biological therapies, not just single-asset drugs, so that companies building the next generation of cancer treatments are not waiting a decade for regulatory clarity .